{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:08:12Z","timestamp":1774566492796,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary hepatic carcinosarcoma is a rare, aggressive tumour with both carcinomatous and sarcomatous components. Limited documented cases hinder comprehensive understanding, making diagnosis, treatment, and management particularly challenging for clinicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 62-year-old female, with prior cervical squamous cell carcinoma 7 years ago, underwent right hemihepatectomy, cholecystectomy, and diaphragmatic resection in 2025. Grossly, a 180 mm white hepatic tumour with a large cystic cavity was seen adherent to the diaphragm, extending to the resection margin (R2), while the hepatic resection margin was clear (R0). Histology confirmed hepatic carcinosarcoma (pT4), comprising cholangiocarcinoma (CK7, BerEP4+), hepatocellular carcinoma (Glypican-3+), and squamous carcinoma (p63, p40+). Sarcomatous areas included rhabdomyosarcomatous (Desmin, Myogenin, MyoD1+), leiomyosarcomatous (SMA+), and chondrosarcomatous (S100+) differentiation. PLAP and CD117 positivity suggested germ cell-like features. There is no distinct separation between the carcinomatous and sarcomatous components. Molecular profiling revealed a KIAA1549::BRAF fusion alongside oncogenic variants: TERT c.-124C&amp;gt;T (VAF 0.60) and TP53 c.811G&amp;gt;A p. (Glu271Lys) (VAF 0.90). Targeted panel sequencing showed no other actionable mutations. MSI readout was 2.5%, confirming microsatellite stability (MSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>Multidisciplinary review at tertiary centres confirmed the rarity and grave outlook. The patient developed early recurrence with thoraco-abdominal deposits, venous thromboembolism, and pleural effusion. Paclitaxel\u2013carboplatin chemotherapy was commenced with dose modifications for hepatotoxicity, complicated by infusion reactions, mild neuropathy, and mucositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underlines the extreme morphological and molecular heterogeneity of hepatic carcinosarcomas, the rapid progression despite surgery, and the limited systemic treatment options available for such rare tumours.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1759219","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:39:10Z","timestamp":1769765950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic carcinosarcoma: a rare and aggressive case with unusual molecular signature!"],"prefix":"10.3389","volume":"16","author":[{"given":"Sayed Ali","family":"Almahari","sequence":"first","affiliation":[{"name":"Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, Queen\u2019s Medical Center","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Al-Ani","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nottingham University Hospitals NHS Trust, City Hospital","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abed M","family":"Zaitoun","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, Queen\u2019s Medical Center","place":["Nottingham, United Kingdom"]},{"name":"Nottingham Digestive Diseases Centre, Division of Translational Medical Sciences, School of Medicine, University of Nottingham, Queen\u2019s Medical Centre","place":["Nottingham, United Kingdom"]},{"name":"National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen\u2019s Medical Centre","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Nottingham University Hospitals NHS Trust, Queen\u2019s Medical Center","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samiya","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, Queen\u2019s Medical Center","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nottingham University Hospitals NHS Trust, City Hospital","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahaaeldin","family":"Baraka","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nottingham University Hospitals NHS Trust, City Hospital","place":["Nottingham, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40644-018-0141-0","article-title":"Primary carcinosarcoma of the liver: imaging features and clinical findings in six cases and a review of the literature","volume":"18","author":"Li","year":"2018","journal-title":"Cancer Imaging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1665-2681(19)31015-4","article-title":"Hepatic carcinosarcoma: clinicopathologic features and a review of the literature","volume":"12","author":"Lin","year":"2013","journal-title":"Ann Hepatol"},{"key":"B3","article-title":"Classification of tumours editorial board","volume-title":"Digestive System Tumours","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1440-1827.2011.02665.x","article-title":"Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases","volume":"61","author":"Nakanuma","year":"2011","journal-title":"Pathol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870115)59:2<310::AID-CNCR2820590224>3.0.CO;2-S","article-title":"Hepatocellular carcinoma with sarcomatous change. Clinicopathologic and immunohistochemical studies of 14 autopsy cases","volume":"59","author":"Kakizoe","year":"1987","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-012-1946-y","article-title":"Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver","volume":"16","author":"Wang","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"B7","first-page":"679","article-title":"Miscellaneous tumors and tumor-like lesions of the liver","volume-title":"Practical hepatic pathology: a diagnostic approach","author":"Saxena","year":"2018"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i5.652","article-title":"Primary mixed germ cell tumor of the liver with sarcomatous components","volume":"16","author":"Xu","year":"2010","journal-title":"World J Gastroenterol"},{"key":"B9","article-title":"Yolk sac differentiation of cholangiocarcinoma \u2013 an intriguing and recherch\u00e9 case","volume":"10","author":"Raja","year":"2023","journal-title":"Int J Res Anal Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1333926","article-title":"High immune cell infiltration predicts improved survival in cholangiocarcinoma","volume":"14","author":"Wirta","year":"2024","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103375","article-title":"Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target","volume":"67","author":"Zhou","year":"2021","journal-title":"EBioMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/path.2558","article-title":"Activation of the ERK\/MAPK pathway: A signature of low-grade astrocytomas","volume":"218","author":"Forshew","year":"2009","journal-title":"J Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0617","article-title":"Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","volume":"4","author":"Chmielecki","year":"2014","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155806","article-title":"Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population","volume":"266","author":"Hwang","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oncolo\/oyad247","article-title":"Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers","volume":"29","author":"Rustgi","year":"2024","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/17512433.2024.2418405","article-title":"Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma","volume":"17","author":"Zhang","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1634\/theoncologist.2017-0645","article-title":"Hybrid capture-based tumor sequencing and copy number analysis to confirm origin of metachronous metastases in BRCA1-mutant cholangiocarcinoma harboring a novel YWHAZ-BRAF fusion","volume":"23","author":"Lim","year":"2018","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1759219\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:39:11Z","timestamp":1769765951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1759219\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1759219"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1759219","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1759219"}}